Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,509 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard IL, Richardson GE, Sessa C, Yonemori K, Banerjee S, Leary A, Tinker AV, Jung KH, Madry R, Park SY, Anderson CK, Zohren F, Stewart RA, Wei C, Dychter SS, Monk BJ. Pujade-Lauraine E, et al. Among authors: wei c. Lancet Oncol. 2021 Jul;22(7):1034-1046. doi: 10.1016/S1470-2045(21)00216-3. Epub 2021 Jun 15. Lancet Oncol. 2021. PMID: 34143970 Clinical Trial.
TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.
Mitri Z, Nanda R, Blackwell K, Costelloe CM, Hood I, Wei C, Brewster AM, Ibrahim NK, Koenig KB, Hortobagyi GN, Van Poznak C, Rimawi MF, Moulder-Thompson S; Translational Breast Cancer Research Consortium. Mitri Z, et al. Among authors: wei c. Clin Cancer Res. 2016 Dec 1;22(23):5706-5712. doi: 10.1158/1078-0432.CCR-15-2845. Epub 2016 May 10. Clin Cancer Res. 2016. PMID: 27166393 Clinical Trial.
Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes.
McAvoy S, Ciura K, Wei C, Rineer J, Liao Z, Chang JY, Palmer MB, Cox JD, Komaki R, Gomez DR. McAvoy S, et al. Among authors: wei c. Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):819-27. doi: 10.1016/j.ijrobp.2014.07.030. Epub 2014 Sep 11. Int J Radiat Oncol Biol Phys. 2014. PMID: 25220718
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, Moulder S, Pusztai L, Hatzis C, Hortobagyi GN. Symmans WF, et al. Among authors: wei c. J Clin Oncol. 2017 Apr 1;35(10):1049-1060. doi: 10.1200/JCO.2015.63.1010. Epub 2017 Jan 30. J Clin Oncol. 2017. PMID: 28135148 Free PMC article.
Malignant melanoma in teenagers and young adults.
Kolandijan NA, Wei C, Burke A, Bedikian AY. Kolandijan NA, et al. Among authors: wei c. J Pediatr Hematol Oncol. 2014 Oct;36(7):552-8. doi: 10.1097/MPH.0000000000000231. J Pediatr Hematol Oncol. 2014. PMID: 25089601
Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors.
Dasari A, Phan A, Gupta S, Rashid A, Yeung SC, Hess K, Chen H, Tarco E, Chen H, Wei C, Anh-Do K, Halperin D, Meric-Bernstam F, Yao J. Dasari A, et al. Among authors: wei c. Endocr Relat Cancer. 2015 Jun;22(3):431-41. doi: 10.1530/ERC-15-0002. Epub 2015 Apr 21. Endocr Relat Cancer. 2015. PMID: 25900182 Free PMC article. Clinical Trial.
Proton beam therapy and concurrent chemotherapy for esophageal cancer.
Lin SH, Komaki R, Liao Z, Wei C, Myles B, Guo X, Palmer M, Mohan R, Swisher SG, Hofstetter WL, Ajani JA, Cox JD. Lin SH, et al. Among authors: wei c. Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):e345-51. doi: 10.1016/j.ijrobp.2012.01.003. Epub 2012 Mar 13. Int J Radiat Oncol Biol Phys. 2012. PMID: 22417808 Free PMC article.
A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer.
Mitri Z, Karakas C, Wei C, Briones B, Simmons H, Ibrahim N, Alvarez R, Murray JL, Keyomarsi K, Moulder S. Mitri Z, et al. Among authors: wei c. Invest New Drugs. 2015 Aug;33(4):890-4. doi: 10.1007/s10637-015-0244-4. Epub 2015 May 7. Invest New Drugs. 2015. PMID: 25947565 Clinical Trial.
8,509 results